Cost-Effectiveness of Digital HIV Self-Testing

By Crystal Lubbe

February 4, 2025

 Is digital innovation the key to enhancing HIV testing in high-prevalence regions? The article evaluates the cost-utility of digital HIV self-testing (HIVST) with digital supports in Malawi, South Africa, and Brazil. A Markov model compares the cost-effectiveness of digital HIVST to community-based and facility-based testing. Digital HIVST is cost-effective, especially for key populations with high HIV test-positivity rates. This approach improves linkage to care and ART initiation.

Key Insights on Digital HIV self-testing 

  • Cost-Effectiveness: Digital HIV self-testing is cost-effective compared to facility-based testing. ICERs range from $769 to $17,839 per DALY averted.
  • Linkage to Care: Linkage to care is crucial for cost-effectiveness. Required linkage rates vary from 20% to 48% by country.
  • Digital Supports: Text messaging and online platforms boost digital HIVST uptake, especially among hard-to-reach groups.
  • Country-Specific Outcomes: Cost-utility varies by country. Malawi has the lowest ICER, Brazil the highest, due to cost differences.
  • Key Drivers: Cost-utility drivers include HIVST cost, test-positivity rates, care linkage, and ART initiation rates.

Relevance to Global HIV Strategies

The study aligns with global HIV goals set by the United Nations, which aim to enhance HIV diagnosis and care by 2030. These goals emphasise innovative strategies, such as HIVST, to increase testing uptake. Previous studies have shown that HIVST can be cost-effective with community supports. However, there is limited data on the cost-utility of digital HIVST approaches. This study follows WHO CHOICE guidelines and uses GDP-based willingness-to-pay thresholds, a common method in health economic evaluations.

Implications for Health Policy and Research

The findings suggest that digital HIVST is a highly cost-effective method for increasing HIV testing and improving care linkage, particularly in regions with high HIV prevalence and limited access to conventional testing. Policymakers should consider incorporating digital HIVST into their testing strategies, focusing on key populations with high rates of undiagnosed HIV. Strategies to enhance cost-utility include ensuring adequate linkage to care, negotiating reduced test costs, and leveraging digital technologies to improve accessibility. While digital HIVST offers many benefits, it may not suit all populations due to disparities in internet and device access. A balanced approach that combines digital and traditional methods is essential to ensure health equity.

Further research is needed to assess the long-term impact of HIVST on community HIV incidence and the cost-effectiveness of various digital strategies. Addressing limitations in current studies, such as the lack of dynamic transmission modeling and limited costing data for digital HIVST, is also vital.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.